Evidence map›Paper›PMID 19932449›Full record

ReviewPhotodiagnosis and photodynamic therapy

Photodynamic therapy for localized infections--state of the art.

Tianhong Dai, Ying-Ying Huang, Michael R Hamblin

Registry-linked trialAbstract readReview
In one paragraph

Review in Photodiagnosis and photodynamic therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07494773 (Topical Methylene Blue-Photodynamic Therapy), which is not on this map. Cited by 229 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
229citing papers in PubMed, 4 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07494773 early_phase1not yet recruitingnot on this map

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection: A Prospective Randomized Pilot Study

TypeinterventionalSponsorUniversity of OklahomaRan2026 to 2028Enrolled50ConditionsBurns, Wound InfectionArmsMethylene Blue, Blue Light Illumination
3 · Its place in the literature

Who cites it

229 citing papers in PubMed, 4 syntheses or guidelines pooled it, 770 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. A combination of photodynamic therapy and antimicrobial compounds to treat skin and mucosal infections: a systematic review.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2019
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Hydralazine potentiates the antiproliferative effect of photodynamic therapy on Candida albicans and Candida parapsilosis in vitro.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  12. Review
  13. Advances in carrier-free nanodrug delivery systems.Drug delivery and translational research · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Photodynamic Therapy in Dermatology.International journal of molecular sciences · 2026
    Review
  18. Siderophore-Porphyrin conjugates for bacteria-selective antimicrobial photodynamic therapy.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Article
  19. Article
  20. Review

169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Tianhong DaiWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114-2696, USA.
Ying-Ying Huang
Michael R Hamblin
Massachusetts General Hospital · USHarvard University · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
NIAID NIH HHS R01 AI050875NIAID NIH HHS R01AI050875
6 · The paper itself

Abstract

Photodynamic therapy (PDT) was discovered over 100 years ago by observing the killing of microorganisms when harmless dyes and visible light were combined in vitro. Since then it has primarily been developed as a treatment for cancer, ophthalmologic disorders and in dermatology. However, in recent years interest in the antimicrobial effects of PDT has revived and it has been proposed as a therapy for a large variety of localized infections. This revival of interest has largely been driven by the inexorable increase in drug resistance among many classes of pathogen. Advantages of PDT include equal killing effectiveness regardless of antibiotic resistance, and a lack of induction of PDT resistance. Disadvantages include the cessation of the antimicrobial effect when the light is turned off, and less than perfect selectivity for microbial cells over host tissue. This review will cover the use of PDT to kill or inactivate pathogens in ex vivo tissues and in biological materials such as blood. PDT has been successfully used to kill pathogens and even to save life in several animal models of localized infections such as surface wounds, burns, oral sites, abscesses and the middle ear. A large number of clinical studies of PDT for viral papillomatosis lesions and for acne refer to its antimicrobial effect, but it is unclear how important this microbial killing is to the overall therapeutic outcome. PDT for periodontitis is a rapidly growing clinical application and other dental applications are under investigation. PDT is being clinically studied for other dermatological infections such as leishmaniasis and mycobacteria. Antimicrobial PDT will become more important in the future as antibiotic resistance is only expected to continue to increase.

Indexed as

Drug Resistance, MultiplePhotochemotherapyAnti-Bacterial AgentsHumansInfectionsModels, BiologicalPhotosensitizing AgentsAnti-Bacterial AgentsPhotosensitizing Agents

Identifiers

PMID19932449
PMCPMC2811240
OpenAlexW2112148102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.